Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia.

Nature reviews. Clinical oncology·2026
Same author

From ASCO 2026.

Nature reviews. Clinical oncology·2026
Same author

Pan-RAS inhibitor daraxonrasib shows promise in pancreatic cancer.

Nature reviews. Clinical oncology·2026
Same author

Lisocabtagene maraleucel has high efficacy in R/R MZL.

Nature reviews. Clinical oncology·2026
Same author

CDK4/6 inhibition provides additional efficacy in HER2<sup>+</sup>, HR<sup>+</sup> breast cancer.

Nature reviews. Clinical oncology·2026
Same author

MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma.

Nature reviews. Clinical oncology·2026

Related Experiment Video

Updated: Feb 27, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K

Immunotherapy: PD-1 blockade exploiting MMR deficiency

David Killock

    Nature Reviews. Clinical Oncology
    |June 28, 2017
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
    10:18

    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

    Published on: July 7, 2023

    1.8K
    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
    06:07

    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

    Published on: February 5, 2020

    6.2K

    Related Experiment Videos

    Last Updated: Feb 27, 2026

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
    07:04

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

    Published on: May 2, 2025

    1.2K
    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
    10:18

    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

    Published on: July 7, 2023

    1.8K
    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
    06:07

    Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

    Published on: February 5, 2020

    6.2K